News

Full-Life Technologies, a fully integrated global radiotherapeutics company, announced an agreement to acquire New Jersey-based Focus-X Therapeutics, a company developing targeted…
Read More...

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced that it has entered into an evaluation and option agreement with ADC Therapeutics SA. Biocytogen will grant ADC Therapeutics a…
Read More...

The Global Antibiotic Research and Development Partnership (GARDP) and Mitsubishi Tanabe Pharma Corporation (MTPC) have signed an agreement for GARDP to access over 50,000 compounds…
Read More...

AbbVie announced the European Commission (EC) approved SKYRIZI (risankizumab, 600 mg intravenous induction and 360 mg subcutaneous maintenance therapy) as the first specific…
Read More...

Xeris Biopharma Holdings, Inc. a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range of…
Read More...

XtalPi announced that they are embarking on a strategic collaboration with CK Life Sciences, a member of the CK Hutchison Group. XtalPi and CK Life Sciences will leverage their…
Read More...

Sirona Biochem Corp. announces that, subsequent to the LOI, Sirona and Wanbang Biopharmaceuticals (“Wanbang”) have signed an expanded, international partnership agreement to collaborate…
Read More...

FUJIFILM Corporation announced a $188 million investment to establish a cell culture media manufacturing facility in Research Triangle Park (RTP), North Carolina, USA. The new site will…
Read More...

Regeneron Pharmaceuticals, Inc. and CytomX Therapeutics, Inc. announced a collaboration and licensing agreement to create conditionally-activated investigational bispecific cancer…
Read More...

Roche announced that the U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for cobas MPXV for use on the cobas 6800/8800 Systems. The test is a real time…
Read More...

IVERIC bio, Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for avacincaptad pegol (ACP, also known as Zimura), a novel…
Read More...

Takeda announced that the randomized, Phase 3 PhALLCON trial met its primary endpoint, demonstrating that adult patients with newly-diagnosed Philadelphia chromosome-positive acute…
Read More...

Alexion, AstraZeneca Rare Disease, announced the completion of its acquisition of LogicBio Therapeutics, Inc. The acquisition creates an opportunity to accelerate Alexion’s growth in…
Read More...

Horizon Therapeutics plc announced that it has entered a multi-year scientific collaboration with Johns Hopkins University School of Medicine to identify new disease targets and develop…
Read More...

Ascletis Pharma Inc. announces the approval of the Investigational New Drug (IND) application by China National Medical Products Administration (NMPA) for the in-house developed oral…
Read More...

Idorsia Ltd, specialized in the discovery, development and commercialization of small molecules to transform the horizon of therapeutic options, and Simcere Pharmaceutical Group Ltd, an…
Read More...

Ferring Pharmaceuticals and Gubra entered into a collaboration agreement to further develop and characterize preclinical animal models of inflammatory bowel disease (IBD). The…
Read More...

ElevateBio, LLC (ElevateBio), a technology-driven company focused on powering transformative cell and gene therapies, and Affini-T Therapeutics, a biotechnology company unlocking the…
Read More...

NextCure, Inc. and LegoChem Biosciences, Inc. announced a collaboration and co-development agreement focused on generating a B7-H4 antibody drug conjugate (ADC) and options for two…
Read More...

Jnana Therapeutics, a biotechnology company leveraging its next-generation chemoproteomics platform to discover medicines for challenging-to-drug targets, announced the company has…
Read More...